Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment

A major problem in pharmaceutical development is that adverse effects remain undetected during preclinical and clinical trials, but are later revealed after market release when prescribed to many patients. We have developed a fitness assay known as the organismal performance assay (OPA), which evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaukler, Shannon M., Ruff, James S., Galland, Tessa, Underwood, Tristan K., Kandaris, Kirstie A., Liu, Nicole M., Morrison, Linda C., Veranth, John M., Potts, Wayne K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869410/
https://www.ncbi.nlm.nih.gov/pubmed/27247619
http://dx.doi.org/10.1111/eva.12365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869410/
https://www.ncbi.nlm.nih.gov/pubmed/27247619
http://dx.doi.org/10.1111/eva.12365

Ejemplares similares